Study of ABO2102 in KRAS-Mutated Solid Tumors
Study of ABO2102 in KRAS-Mutated Solid Tumors
Recruiting · NCT07455617 · Registry updated 2026-04-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of ABO2102 in KRAS-Mutated Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-04-06 | NCT07455617 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abogen Biosciences (Shanghai) Co., Ltd | 6 |
| Suzhou Abogen Biosciences Co., Ltd. | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | China | 23 |